H
Harry H. Yoon
Researcher at Mayo Clinic
Publications - 88
Citations - 4131
Harry H. Yoon is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 24, co-authored 72 publications receiving 2636 citations. Previous affiliations of Harry H. Yoon include Johns Hopkins University & Ohio State University.
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs,Toshihiko Doi,Raymond Jang,Raymond Jang,Kei Muro,Taroh Satoh,Manuela Machado,Weijing Sun,Weijing Sun,Shadia I. Jalal,Manish A. Shah,Jean Phillipe Metges,Marcelo Garrido,Talia Golan,Talia Golan,Mario Mandalà,Zev A. Wainberg,Daniel V.T. Catenacci,Atsushi Ohtsu,Kohei Shitara,Ravit Geva,Jonathan Bleeker,Andrew H. Ko,Geoffrey Y. Ku,Philip A. Philip,Peter C. Enzinger,Yung-Jue Bang,Diane Levitan,Jiangdian Wang,Minori Koshiji Rosales,Rita P. Dalal,Harry H. Yoon +31 more
TL;DR: Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment.
Journal ArticleDOI
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Jaffer A. Ajani,Thomas A. D'Amico,David J. Bentrem,Joseph Chao,David Cooke,Carlos U. Corvera,Prajnan Das,Peter C. Enzinger,Thomas Enzler,Paul T. Fanta,Farhood Farjah,Hans Gerdes,C. Michael Gibson,Steven N. Hochwald,Wayne L. Hofstetter,David H. Ilson,Rajesh N. Keswani,Sunnie Kim,Lawrence Kleinberg,Samuel J. Klempner,Jill Lacy,Quan P. Ly,Kristina A. Matkowskyj,Michael McNamara,Mary F. Mulcahy,Darryl Alan Outlaw,Haeseong Park,Kyle A. Perry,Jose M. Pimiento,George A. Poultsides,Scott I. Reznik,Robert Ross,Vivian E. Strong,Stacey Su,Hanlin L. Wang,Georgia L. Wiesner,Christopher G. Willett,Danny Yakoub,Harry H. Yoon,Nicole R. McMillian,Lenora A. Pluchino +40 more
TL;DR: Palliative management, which may include systemic therapy, chemoradiation, and/or best supportive care, is recommended for all patients with unresectable or metastatic cancer.
Journal ArticleDOI
Long-term seizure outcome in patients initially seizure-free after resective epilepsy surgery
TL;DR: In patients seizure-free during the first year after resective epilepsy surgery, the likelihood of remaining seizure- free declined to 56% over 10 years, but half of patients who relapsed had at most one seizure per year.
Journal ArticleDOI
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.
Charles S. Fuchs,Toshihiko Doi,Raymond Woo-Jun Jang,Kei Muro,Taroh Satoh,Manuela Machado,Weijing Sun,Shadia I. Jalal,Manish A. Shah,Jean-Philippe Metges,Marcelo Garrido,Talia Golan,Mario Mandalà,Zev A. Wainberg,Daniel V.T. Catenacci,Yung-Jue Bang,Jiangdian Wang,Minori Koshiji,Rita P. Dalal,Harry H. Yoon +19 more
TL;DR: A global, multicohort, phase 2 study of pembro in pts with advanced gastric or gastroesophageal junction (G/GEJ) cancer with promising antitumor activity and manageable safety and primary end points: ORR, safety, and tolerability.
Journal ArticleDOI
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Yung Jue Bang,Yoon-Koo Kang,Daniel V.T. Catenacci,Kei Muro,Charles S. Fuchs,Ravit Geva,Hiroki Hara,Talia Golan,Marcelo Garrido,Shadia I. Jalal,Christophe Borg,Toshihiko Doi,Harry H. Yoon,Mary J. Savage,Jiangdian Wang,Rita P. Dalal,Sukrut Shah,Zev A. Wainberg,Hyun Cheol Chung +18 more
TL;DR: Pembrolizumab demonstrated antitumor activity and was well tolerated as monotherapy and in combination with chemotherapy in patients with previously untreated advanced gastric/gastroesophageal junction adenocarcinoma.